title: Blood safety and the choice of anti-hemophilic factor concentrate.
abstract: Hemophilia is a congenital disorder due to the deficiency of the activity of factor VIII (classical hemophilia A) or IX (Christmas disease or hemophilia B). Bleeding is common and may result in long-term complications or even death. Bleeding may be treated or prevented by infusion of factor concentrates however these drugs are not without risk. Clinicians often feel ill prepared to provide accurate and impartial information regarding these drugs. This review will provide the reader with an historical yet up to date perspective on blood safety as it relates to the choice of concentrates to treat hemophilia.
authors.affiliation: RUSH Hemophilia and Thrombophilia Center, Department of Pediatrics, Rush University Medical Center, Chicago, Illinois 60612, USA. lvalentino@rush.edu
authors.forename: Leonard A
authors.initials: LA
authors.lastname: Valentino
authors.forename: Veeral M
authors.initials: VM
authors.lastname: Oza
mesh_terms: D001782:Blood Donors; D017848:Blood-Borne Pathogens; D005164:Factor IX / Q000009:adverse effects* / Q000627:therapeutic use; D005169:Factor VIII / Q000009:adverse effects* / Q000627:therapeutic use; D006467:Hemophilia A / Q000628:therapy*; D006801:Humans; D012307:Risk Factors; D012449:Safety
chemical_list: D005169:Factor VIII; D005164:Factor IX